Overview

Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization

Status:
Completed

Trial end date:
2009-10-01

Target enrollment:

Participant gender:

Summary

This study evaluated the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity and anatomic outcomes compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Ranibizumab
Verteporfin